Clearside Biomedical (CLSD) Stock Price

Clearside Biomedical Price

NASDAQ·CLOSED
0.41
​
Market closed

Over the last 8 years Clearside Biomedical grew revenue by 15.6% annually, reaching 1.66 M USD. For Clearside Biomedical, the net margin of -2,064.4% is down versus -230.8% a few years ago.

Clearside Biomedical stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical business model & stock analysis

Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively.

Frequently asked questions about Clearside Biomedical

9 analysts currently rate the Clearside Biomedical stock: 0 recommend buying, 6 holding and 3 selling.

Converted at the current exchange rate, the Clearside Biomedical share trades at 0.37 EUR (0.41 USD).

The Clearside Biomedical share (CLSD) is listed on 4 stock exchanges, including: NASDAQ (CLSD), Frankfurt (CLM.F), München (CLM.MU), Düsseldorf (CLM.DU).

The revenue cannot currently be calculated for Clearside Biomedical.

The expected profit of Clearside Biomedical is -13.60 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Clearside Biomedical is currently -0.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Clearside Biomedical stock.

The P/S cannot be calculated for Clearside Biomedical currently.

The Eulerpool Quality Score for Clearside Biomedical is 5/10.

The ISIN of Clearside Biomedical is US1850632035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Clearside Biomedical is A2ALP6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Clearside Biomedical is CLSD. The ticker symbol is used to trade Clearside Biomedical shares on the stock exchange.

Fair ValueTerminal
0.34 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
50,424.24 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 2, 2016
ISIN
US1850632035
Cusip
185063104
Sedol
BZ6VT37
Market capitalization
2.14 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.13
P/Ee 2026
-0.15
P/Ee 2027
-0.15
P/Ee 2028
-0.50
P/Ee 2029
0.03
P/S
P/Se
0.63
EV/EBIT
0.62
P/B Ratio
0.20
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
88.41 %
Last updated Nov 19, 2026, 7:57 PM

Clearside Biomedical Ticker

DÜSSELDORF · CLM.DUFRANKFURT · CLM.FMUNICH · CLM.MUNASDAQ · CLSD